share_log

Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target

Benzinga ·  Jun 22, 2023 07:16

Oppenheimer analyst Francois Brisebois upgrades DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announces $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment